Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Roche's Genentech published Phase III data for faricimab in wet AMD and DME • Source: Shutterstock

Roche Holding AG’s Genentech is looking to retain its position in the ophthalmology market as one of its leading products faces market erosion due to biosimilar competition while gene therapy competitors potentially gain ground as well. The publication of Phase III data for its bispecific antibody faricimab in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) reinforces the drug’s market potential, particularly the possibility of less-frequent dosing resulting in fewer patients lost to follow-up.

Faricimab, a bispecific antibody targeting vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), is under US Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Sensory

More from Therapy Areas

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.